containing HLA-A2 tetramers, and effi ciently recognized target-cells pulsed with low nM concentrations of ErbB2 369-377 peptide as well as non-pulsed ErbB2 + HLA-A2 + tumor cell lines in vitro. In a novel xenograft model, ErbB2-redirected T-cells also signifi cantly delayed progression of ErbB2 + HLA-A2 + human tumor in vivo. Together, these results support the notion that redirection of normal T-cell specifi city by TCR gene transfer can have potential applications in the adoptive immunotherapy of ErbB2-expressing malignancies.
Genetic modifi cation of allogeneic T cells to express antigenspecifi c receptors provides an opportunity to redirect immunity against particular tumour associated or viral antigens. Cord blood T cells (CB-T cells) have a naïve phenotype and mediate potent antiviral and anti-leukaemia effects following allogeneic transplantation with reduced graft versus host disease compared to peripheral blood grafts. Single cord blood donations have a fi nite cell dose and it is not unusual to pool matched or partially matched donations, and this provides an important rationale and opportunity to supplement grafts with engineered T cells from a second donation. We have investigated the feasibility of genetically engineering CBT for directed anti-tumour activity using lentiviral transfer of antigen specifi c receptors CB was fi colled and cells activated with different stimulation: either CD3/ CD28 antibodies and IL-2 or a combinations of IL-2 , IL-7 and IL-15 then exposed to a single round of lentiviral transduction with selfinactivating vector expressing recombinant T cell receptors or a second generation chimeric antigen receptor (CAR). Flow cytometric analysis found a mean of 70% (49-95%) gene transfer in bead activated cells and a 38% (26-47%) in T cell populations stimulated with cytokines alone. Modifi ed cells exhibited antigen specifi c target cell lysis, with cytokine stimulated populations retaining markers of naive phenotype. Next the possibility of producing non-alloreactive, TCR depleted, CAR19 expressing cord T cells was evaluated. Endogenous αb TCR expression was disrupted using transcription activator-like effector nucleases (TALENs) targeting the constant domain of the TCR α chain. Initially, plasmid mediated expression of TALEN pairs was linked to distinct fl ow detectable tag proteins whereby co-expression of both marker proteins correlated with disruption of TCR expression. Subsequently, electroporation of TALEN mRNA into cord blood T cells transduced with CAR19 yielded populations of antigen specifi c T cells with reduced alloreactive potential. Such cord blood T cells hold potential as an "off-the-shelf" therapy for treatment of B-lineage malignancies, in particular when autologous T cells are unsuitable and well matched allogeneic donors are unavailable. We have previously shown that systemically-administered Vesicular Stomatitis Virus (VSV) encoding Tumor Associated Antigens (TAAs) can break tolerance to self-TAA and generate anti-tumor immunogenicity against subcutaneous tumors. Here we extended this approach to the treatment of brain tumors. Thus, we observed that T cell responses generated when single self-antigens (such as gp100, ED-B or Ephrin) were displayed in the viral vector were not potent enough to generate cures in animals with established brain tumors. However, combination of i.v. treatment with VSV encoding hgp100, with adoptive T cell transfer of naïve PMel T cells, generated effective immunotherapy against B16ova tumors implanted in the brain, with over 75% of mice alive after 100 days. In order to boost the T cell responses induced by VSV-TAA alone, thereby removing the need for the co-administration of adoptive T cell therapy, we are testing a prime-boost strategy to amplify the initial VSV-TAA induced T cell response. In this respect, we have shown that combinations of viral vectors, including Ad, VSV and TMEV, encoding for a single TAA, in a prime-boost setting, can signifi cantly enhance the immunogenicity of the TAA, compared to its use in a single vector, to treat B16ova brain tumors. In addition, building on our experience with the use of multiple TAA expressed from VSV to treat s.c. tumors, we have also shown that combining the expression of three different self antigens from systemically delivered VSV signifi cantly prolonged survival of mice bearing intra-cranial GL261 gliomas compared to treatment with VSV-GFP alone (P<0.001). These antigens, induced by the local tumor microenvironment, served as effective immunogens against different tumor types growng intracranially. Therefore, we are currently testing prime-boost strategies in which combinations of different viral vectors, displaying different TAA, are used to treat mice with established brain tumors.
Viral Vectors Encoding and Displaying Tumor Associated Antigens Used in Prime-Boost Strategies for Brain Tumor Immunotherapy

Development of Inducible Switch Promoters That Drive Exogenous Gene Expression Upon the Recognition of CD19 by Chimeric Antigen Receptors
Ryosuke Uchibori, 1,2 Soranobu Ninomiya, 2 Tomonori Tsukahara, 1,2 Hiroyuki Ido, 1, 3 The adoptive transfer of T cells that express a chimeric antigen receptor (CAR) is a promising cell-based anticancer therapy. Although clinical studies of CAR T cell-based therapies have shown therapeutic effi cacy, additional genetic modifi cations of the cells are needed to enhance effi cacy and safety. For example, antitumor cytokine production by CAR T cells can potentially enhance tumor-killing activity, but constitutive expression of such molecules could also cause systemic side effects. Therefore, it is important to confi ne exogenous gene expression by CAR T cells to the tumor vicinity.
